Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the <scp>TOP</scp> ‐ <scp>ELM</scp> study
Short-term tofogliflozin therapy did not improve the insulin secretory capacity of treatment-naïve people with type 2 diabetes. However, tofogliflozin may facilitate the early recovery of insulin secretory capacity in individuals with poor glucose tolerance.
Authors
- K Okada (ORCID: https://orcid.org/0000-0002-3601-7969)
- Mayuko Ono
- AIKA MIYA
- Shingo Yanagiya
- Hiraku Kameda (ORCID: https://orcid.org/0000-0003-1870-6688)
- Maiko Miyamoto (ORCID: https://orcid.org/0009-0000-8074-519X)
- Kyu Yong Cho (ORCID: https://orcid.org/0000-0002-3131-0832)
- Takahiro Takase (ORCID: https://orcid.org/0000-0001-6089-2395)
- Kiyohiko Takahashi (ORCID: https://orcid.org/0000-0002-3962-4078)
- Tatsuya Atsumi
- Yuka Takahashi
- Akinobu Nakamura
- TOP‐ELM study group
- Yuki Yamauchi
Institutions
- Hokkaido University (JP)
- NTT Medical Center (JP)
- Tonan Hospital (JP)
- Obihiro Kosei General Hospital (JP)
- Hokkaido University Hospital (JP)
- Hakodate Central General Hospital (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1111/jdi.70245
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00